Symposiums

This symposium was focused on reviewing androgen deprivation therapy (ADT) in prostate cancer, highlighting the implications of this therapy in clinical…

The glycosaminoglycan (GAG) layer of the bladder represents a mucous layer on the surface of the urothelium. Acting as an antibacterial defence mechanism…

With approximately 150,000 new cases of bladder cancer diagnosed each year, and two-thirds of these being non-muscle invasive bladder cancer (NMIBC)…

Prof Fred Saad began his presentation by introducing the audience to the different prostate cancer disease states. These range from patients with…

This Bristol Myers Squibb-sponsored symposium was chaired by Mark Thursz, who oversaw a novel news bulletin-themed symposium with sessions provided by a …

This Gilead-sponsored satellite symposium addressed the new and exciting advent of novel therapy in the field of hepatitis C by highlighting recent…

This educational seminar, supported by an independent educational grant from Daiichi Sankyo, was held at the AHA congress in Dallas on 19th November 2013.

The following is an executive summary of the abstract presentation by Prof Robert Giugliano on the ENGAGE AF – TIMI 48 trial primary results.